Gabor Egervari1, Joseph Landry1, James Callens1, John F Fullard2, Panos Roussos3, Eva Keller4, Yasmin L Hurd5. 1. Department of Psychiatry, Friedman Brain Institute; Fishberg Department of Neuroscience, Friedman Brain Institute. 2. Department of Psychiatry, Friedman Brain Institute; Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York. 3. Department of Psychiatry, Friedman Brain Institute; Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York; Mental Illness Research, Education, and Clinical Center (VISN 3), James J. Peters VA Medical Center, Bronx, New York. 4. Department of Forensic Medicine, Semmelweis University, Budapest, Hungary. 5. Department of Psychiatry, Friedman Brain Institute; Fishberg Department of Neuroscience, Friedman Brain Institute. Electronic address: Yasmin.Hurd@mssm.edu.
Abstract
BACKGROUND: Opiate abuse and overdose reached epidemic levels in the United States. However, despite significant advances in animal and in vitro models, little knowledge has been directly accrued regarding the neurobiology of the opiate-addicted human brain. METHODS: We used postmortem human brain specimens from a homogeneous European Caucasian population of heroin users for transcriptional and epigenetic profiling, as well as direct assessment of chromatin accessibility in the striatum, a brain region central to reward and emotion. A rat heroin self-administration model was used to obtain translational molecular and behavioral insights. RESULTS: Our transcriptome approach revealed marked impairments related to glutamatergic neurotransmission and chromatin remodeling in the human striatum. A series of biochemical experiments tracked the specific location of the epigenetic disturbances to hyperacetylation of lysine 27 of histone H3, showing dynamic correlations with heroin use history and acute opiate toxicology. Targeted investigation of GRIA1, a glutamatergic gene implicated in drug-seeking behavior, verified the increased enrichment of lysine-27 acetylated histone H3 at discrete loci, accompanied by enhanced chromatin accessibility at hyperacetylated regions in the gene body. Analogous epigenetic impairments were detected in the striatum of heroin self-administering rats. Using this translational model, we showed that bromodomain inhibitor JQ1, which blocks the functional readout of acetylated lysines, reduced heroin self-administration and cue-induced drug-seeking behavior. CONCLUSIONS: Overall, our data suggest that heroin-related histone H3 hyperacetylation contributes to glutamatergic transcriptional changes that underlie addiction behavior and identify JQ1 as a promising candidate for targeted clinical interventions in heroin use disorder.
BACKGROUND:Opiate abuse and overdose reached epidemic levels in the United States. However, despite significant advances in animal and in vitro models, little knowledge has been directly accrued regarding the neurobiology of the opiate-addicted human brain. METHODS: We used postmortem human brain specimens from a homogeneous European Caucasian population of heroin users for transcriptional and epigenetic profiling, as well as direct assessment of chromatin accessibility in the striatum, a brain region central to reward and emotion. A ratheroin self-administration model was used to obtain translational molecular and behavioral insights. RESULTS: Our transcriptome approach revealed marked impairments related to glutamatergic neurotransmission and chromatin remodeling in the human striatum. A series of biochemical experiments tracked the specific location of the epigenetic disturbances to hyperacetylation of lysine 27 of histone H3, showing dynamic correlations with heroin use history and acute opiate toxicology. Targeted investigation of GRIA1, a glutamatergic gene implicated in drug-seeking behavior, verified the increased enrichment of lysine-27 acetylated histone H3 at discrete loci, accompanied by enhanced chromatin accessibility at hyperacetylated regions in the gene body. Analogous epigenetic impairments were detected in the striatum of heroin self-administering rats. Using this translational model, we showed that bromodomain inhibitor JQ1, which blocks the functional readout of acetylated lysines, reduced heroin self-administration and cue-induced drug-seeking behavior. CONCLUSIONS: Overall, our data suggest that heroin-related histone H3 hyperacetylation contributes to glutamatergic transcriptional changes that underlie addiction behavior and identify JQ1 as a promising candidate for targeted clinical interventions in heroin use disorder.
Authors: Marc R Mansour; Brian J Abraham; Lars Anders; Alla Berezovskaya; Alejandro Gutierrez; Adam D Durbin; Julia Etchin; Lee Lawton; Stephen E Sallan; Lewis B Silverman; Mignon L Loh; Stephen P Hunger; Takaomi Sanda; Richard A Young; A Thomas Look Journal: Science Date: 2014-11-13 Impact factor: 47.728
Authors: Carla Nasca; Danielle Zelli; Benedetta Bigio; Sonia Piccinin; Sergio Scaccianoce; Robert Nisticò; Bruce S McEwen Journal: Proc Natl Acad Sci U S A Date: 2015-11-16 Impact factor: 11.205
Authors: Tillmann Weber; Miriam A Vogt; Sarah E Gartside; Stefan M Berger; Rafael Lujan; Thorsten Lau; Elke Herrmann; Rolf Sprengel; Dusan Bartsch; Peter Gass Journal: Neuropsychopharmacology Date: 2014-12-30 Impact factor: 7.853
Authors: J L Meyers; M C Salling; L M Almli; A Ratanatharathorn; M Uddin; S Galea; D E Wildman; A E Aiello; B Bradley; K Ressler; K C Koenen Journal: Transl Psychiatry Date: 2015-06-23 Impact factor: 6.222
Authors: Gregory C Sartor; Andrea M Malvezzi; Ashok Kumar; Nadja S Andrade; Hannah J Wiedner; Samantha J Vilca; Karolina J Janczura; Amir Bagheri; Hassan Al-Ali; Samuel K Powell; Peyton T Brown; Claude H Volmar; Thomas C Foster; Zane Zeier; Claes Wahlestedt Journal: J Neurosci Date: 2018-11-30 Impact factor: 6.167
Authors: Nathan P Coussens; G Sitta Sittampalam; Samantha G Jonson; Matthew D Hall; Heather E Gorby; Amir P Tamiz; Owen B McManus; Christian C Felder; Kurt Rasmussen Journal: J Pharmacol Exp Ther Date: 2019-09-03 Impact factor: 4.030